Chinese scientists take the lead in the successful research and development of the tumor suppressor protein p53 targeting drug Panda

Beijing, Shanghai, May 23 (Chen Jing, Zhu fan, Tang Wenjia) p53 gene is an important tumor suppressor gene in human body, which can help normal cells repair gene defects and prevent cancer; it can also make cancer cells apoptosis and treat cancer "P53 transformation medicine team", led by Lu Min, researcher of Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, has been engaged in the research and development of the tumor suppressor protein p53 targeting drug panda, which has officially entered the stage of product development and clinical trials, the reporter learned Wednesday According to reports, p53 targeted drugs may benefit nearly 50% of cancer patients On the same day, Ruijin Hospital held a signing ceremony for scientific research transformation of panda project with relevant bioengineering enterprises Chen Saijuan, director of the National Center for translational medicine (Shanghai) and academician of the Chinese Academy of engineering, attended the signing ceremony According to reports, p53 was originally a powerful "cancer angel" in the human body, but if there is mutation, it will change from "angel" to "devil", and promote the occurrence and metastasis of tumor In human cancer, the probability of p53 mutation is about 50% P53 has always been a hot topic for scientists According to incomplete statistics, at least 45 teams around the world are studying treatment methods for p53 mutation At present, there is no substantial progress in the field of targeting drugs for p53 Lu Min innovatively proposed to domesticate the "cancer devil" - mutated p53 into a "cancer angel" This strategy is known as the cure cancer strategy At the beginning of 2015, researcher Lu Min created the team of p53 basic research transformation medicine The team screened and obtained high-efficient p53 targeting small molecule compound panda It is revealed that the panda project has applied for three global family patents and about 200 claims Qu Jieming, President of Ruijin Hospital, said that in the future, the hospital should not only focus on clinical problems and solve them through scientific research, but also speed up the pace from experimental research to clinical transformation, so that scientific research results can truly benefit the public It is known that the contracted enterprises are the first batch of listed enterprises in gem and key high-tech enterprises of national torch plan (end)